

CURRICULUM SCIENTIFICO E DIDATTICO

Nome	Mario Mandala'
Nato il	29.03.1970
Luogo di Nascita	Piana degli Albanesi (PA)
Residenza	Bergamo, via Enrico Fermi 11
Codice Fiscale	MNDMRA70C29G543D

Formazione

1989	Maturità Liceo Classico: votazione 60/60
1995	Laurea in Medicina e Chirurgia con pieni voti e lode – presso Università cattolica del Sacro Cuore-Roma, Policlinico Gemelli Roma
1995	Abilitazione all'esercizio della professione di Medico Chirurgo
2000	Specializzazione in Oncologia Medica con pieni voti e Lode presso l'Università Milano Statale
2003	Training presso Ospedale Regionale di Bellinzona e Valli - Bellinzona
2004	Diploma ESMO Oncologia Medica
2004	Training Istituto Goustave Roussy
2007	Specializzazione in Ematologia con pieni voti e Lode presso l'Università Milano Statale

Posizione lavorativa attuale

Nome e indirizzo del datore di lavoro	Università studi Perugia
Settore	Oncologia. Oncologo Medikco
Tipo di impiego	Professore associato
Dal 2012 ad oggi	Responsabile Unità semplice

Qualifiche conseguite

2020	Professore associato in Oncologia Medica Università degli studi di Perugia
2019	Abilitazione Professore Associato Disciplina Oncologia MED/06
2019	Professore a contratto Università di Pavia
2019	Tutor International School of Medicine Università Bicocca presso ASST Papa Giovanni XXIII Bergamo
Dal 2012 a oggi	Responsabile Unità semplice nel Dipartimento Oncologia-Ematologia ASST Papa Giovanni XXIII

Incarichi Istituzionali e Scientifici

1. Coordinatore nazionale del melanoma nell'ambito della Rete Tumori Rari.
2. Dal 2011 al 2017 responsabile della ricerca clinica traslazionale dell'Intergruppo Italiano Melanoma (IMI).
3. Dal 2017 Segretario Nazionale IMI.
4. Dal 2018 Chairman systemic therapy EORTC Melanoma group

5. Dal 2019 Presidente eletto dell'Intergruppo Italiano Melanoma (IMI)
6. Dal 2019 Membro Scientific Advisory board Centra-Eastern European Advisory Board

Estensione Linee guida nazionali e internazionali di prestigio

1. Dal 2008 al 2011 Estensore Linee guida ESMO per le complicanze tromboemboliche nei tumori solidi.
2. Dal 2017 ad oggi Estensore per linee guida AIOM del melanoma.
3. Dal 2019 ESMO board ed estensore per linee guida melanoma.
4. Dal 2019 Coordinatore LG AIOM complicanze tromboemboliche tumori solidi

Attività di revisore scientifico per le seguenti riviste

Lancet Oncology
 Journal of Clinical Oncology
 Lancet Hematology
 Cancer
 European Journal of Cancer
 British Journal of Cancer
 Annals of Oncology
 Cancer Treatment Reviews
 Journal of Thrombosis and Haemostasis
 Thrombosis and Hemostasis
 Arteriosclerosis- Thrombosis and Vascular Biology
 Critical Reviews in Oncology and Hematology

Incarichi in Società Scientifiche aventi prestigio nel settore

Dal 2014 al 2016	Coordinatore per la ricerca Clinica e Traslazionale IMI
Dal 2017-oggi	Segretario Nazionale IMI
Dal 2016-oggi	Coordinatore del melanoma Rete Tumori Rari
Dal 2018-oggi	Chairman systemic therapy EORTC Melanoma group
Dal 2019-oggi	Board ESMO Guidelines: Melanoma

Relatore a congressi Nazionali

AIOM

2013 Relatore congresso AIOM Nazionale Sessione educativa
La gestione degli eventi tromboembolici nei pazienti con
cancro

2017 Relatore congresso nazionale AIOM: Profilassi per le
complicanze vascolari trombo-emboliche: quando e come

2018 Relatore congresso nazionale AIOM: terapia adiuvante
melanoma

Grandangolo Oncologia

2014 Relatore gestione complicanze tromboemboliche tumori solidi

2015 Relatore Trattamento del melanoma malattia metastatica

2016 Relatore Trattamento del melanoma in adiuvante

2018 Chairman e relatore Terapia adiuvante melanoma

Grandangolo immunologia

2016 Relatore Novità immunoterapia melanoma

2017 Relatore Novità immunoterapia melanoma

2018 Relatore Novità immunoterapia melanoma

CIPOMO

2013 Congresso nazionale CIPOMO Roma. Relatore Nuove terapie
nel melanoma

Sidemast

2015 Congresso Nazionale SIDEMAST la terapia adiuvante nel
melanoma

Congresso Nazionale SIDEMAST la terapia della malattia
avanzata

SIFO Congresso nazionale farmacisti ospedalieri 2012: Nuove
terapie nel melanoma

Congresso nazionale farmacisti ospedalieri 2017: nuove
terapie nel melanoma

Master IMI

2011 Master Course Pescara “Management del paziente con
melanoma dalla ricerca alla terapia”

2012 Master course Udine “Management del paziente con
melanoma dalla ricerca alla terapia”

2012 Master Course Savona “Management del paziente con
melanoma dalla ricerca alla terapia”

2012 Master Course Firenze “Management del paziente con
melanoma dalla ricerca alla terapia”

2013	Master Course Bergamo “Management del paziente con melanoma dalla ricerca alla terapia”
2013	Master Course Ancona “Management del paziente con melanoma dalla ricerca alla terapia”
2016	Master Course Milano “Management del paziente con melanoma dalla ricerca alla terapia”
2017	Master Course Cagliari “Management del paziente con melanoma dalla ricerca alla terapia”
2017	Master Course Recanati “Management del paziente con melanoma dalla ricerca alla terapia”
2017	Master Course Reggio Emilia “Management del paziente con melanoma dalla ricerca alla terapia”
2019	Master Course Matera “Management del paziente con melanoma dalla ricerca alla terapia”
2019	Master Course Varese “Management del paziente con melanoma dalla ricerca alla terapia”

Workshop Immunologia

2015	Relatore Worhop IMI Immunologia Torino
2015	Relatore Worhop IMI Immunologia Reggio Calabria
2016	Relatore Worhop IMI Immunologia Bari
2016	Relatore Worhop IMI Immunologia Modena
2016	Relatore Worhop IMI Immunologia Verona
2018	Relatore Worhop IMI Immunologia Pisa

IMI Nazionale

2011	Relatore Congresso nazionale Milano IMI
2012	Relatore Congresso nazionale Alghero IMI
2013	Relatore Congresso nazionale Napoli IMI
2014	Relatore Congresso nazionale Treviso IMI
2015	Relatore Congresso nazionale Genova IMI
2016	Relatore Congresso nazionale Ragusa IMI
2017	Relatore Congresso nazionale Milano IMI
2018	Relatore Congresso nazionale Bari IMI

Congressi Internazionali

2014	Relatore Congresso EORTC Melanoma group Rotterdam
2015	Relatore Congresso EORTC Melanoma group Berlino
2016	Relatore Congresso EORTC Melanoma group Milano

2017	Relatore Congresso EORTC Melanoma group Varsavia
2018	Relatore Congresso EORTC Melanoma group Majorca
2018	EGAM Meeting Bruxelles EORTC Relatore
2014	Relatore congresso ESMO 2014 Primary Thromboprophylaxis in cancer patients
2017	Melanoma Bridge Relatore
2018	Melanoma Bridge Relatore
2018	International congress on melanoma Varsavia: Relatore
2019	Relatore Istituto oncologico dr Rosell Management of immune related adverse events: a multidisciplinary approach
2019	Relatore Istituto oncologico Ospedale Civile Barcellona Adjuvant and neoadjuvant therapy in melanoma
2019	Padova Melanoma International: Relatore
2019	Amsterdam ESMO guidelines for melanoma

Affiliazioni a Società Scientifiche

AIOM, ESMO, IMI

Attività organizzativa

Master nell'ambito IMI

Coordinamento seminari formativi presso l'azienda ASST Papa Giovanni XXIII

International Conference of Thrombosis and Haemostasis in Cancer in Bergamo

Coordinatore scientifico

Attività organizzativa studi clinici internazionali con ispezione da parte di enti regolatori Internazionali

2016: Superata Ispezione FDA senza major findings

Progetti Nazionali finanziati con peer review

2007: Progetto di continuità di cura Bando per progetti finalizzati Regione Lombardia:

Durata 12 mesi

Ruolo Ricoperto: Partecipante

2007 AIFA Studio Tosca

Durata: 5 anni

Ruolo Ricoperto: Partecipante

2008 AIFA Studio Comets

Durata: 3 anni

Ruolo Ricoperto: Partecipante

2009: Progetto di utilizzo della chemioterapia a fine vita "Bando per progetti finalizzati Regione Lombardia

Durata: 12 mesi
Ruolo ricoperto: Principal Investigator

2011 AIRC Coagulazione e Tumori
Durata: 5 anni
Ruolo ricoperto: Referente per l'oncologia

Progetti Internazionali con peer review finanziati
Grant EORTC
Morphological variants and molecular profiling of undifferentiated/dedifferentiated melanoma: An
EORTC Melanoma Group Study
Ruolo ricoperto: PI

Ricerche da aziende specialistiche del settore

2016 Studio Vemures Grant Roche Global : Principal Investigator
2017 Studio BRAFres Grant Novartis Global: Principal Investigator
2019 Studio Biotaylor Novartis Global: Principal Investigator

Partecipazione a comitati editoriali di riviste, collane editoriali, enciclopedie e trattati di riconosciuto prestigio

Riviste

Open Access ISRN Oncology: Editorial Board

Melanoma management: Editorial Board

Rivista Cancers (Basel): Editorial Board

European journal Internal Medicine: Editorial board

Collane Editoriali

Titolo Medicina Oncologica Elsevier (ex Bonadonna): Editor Edizione 2013

Titolo: Mechanisms of Drug Resistance in Cancer Therapy published in the Springer book series Handbook of Experimental Pharmacology (HEP): Editor Edizione 2018

Titolo: New therapies in cutaneous malignancies published in the Springer book: Editor Edizione 2020

Attività didattica

Dal 2014 ad oggi

Dal 2019

Dal 2018

Scuola di specializzazione Milano Bicocca

Tutor International school of Medicine Bergamo- Bicocca
University

Master Farmacologia Università studi di Milano

Pubblicazioni censite da medline in inglese in ordine cronologico

1. Massi D, Mihic-Probst D, Schadendorf D, Dummer R, **Mandalà M**. Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications [published online ahead of print, 2020 Jun 23]. *Cancer Treat Rev*.
2. Mandalà M, Galli F, Patuzzo R, et al. Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI). *Eur J Cancer*. 2020;137:30-39. doi:10.1016/j.ejca.2020.07.001
3. Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. *N Engl J Med*. 2020 Sep 2. doi: 10.1056/NEJMoa2005493.
4. Indini A, Mandalà M Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients. *Expert Opin Drug Saf*. 2020 Aug 28. doi: 10.1080/14740338.2020.1817376.
5. Salvati L, Mandalà M, Massi D Melanoma brain metastases: review of histopathological features and immune-molecular aspects. *Melanoma Manag*. 2020 Jun 8;7(2):MMT44. doi: 10.2217/mmt-2019-0021.
6. Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. *Ann Oncol*. 2020 Aug 4:S0923-7534(20)39939-7. doi: 10.1016/j.annonc.2020.07.004.
7. Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Keilholz U ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. *Ann Oncol*. 2020 Aug 4:S0923-7534(20)39940-3. doi: 10.1016/j.annonc.2020.07.005

8. Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, **Mandala M**, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Dębniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hočevár M, Höiom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubiński J, Mackie RM, Malt M, Malvey J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novaković S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butille JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, Schulze HJ, Simms LA, Smithers M, Song F, Swerdlow AJ, van der Stoep N, Kukutsch NA, Visconti A, Wallace L, Ward SV, Wheeler L, Sturm RA, Hutchinson A, Jones K, Malasky M, Vogt A, Zhou W, Pooley KA, Elder DE, Han J, Hicks B, Hayward NK, Kanetsky PA, Brummett C, Montgomery GW, Olsen CM, Hayward C, Dunning AM, Martin NG, Evangelou E, Mann GJ, Long G, Pharoah PDP, Easton DF, Barrett JH, Cust AE, Abecasis G, Duffy DL, Whiteman DC, Gogas H, De Nicolo A, Tucker MA, Newton-Bishop JA; GenoMEL Consortium; Q-MEGA and QTWIN Investigators; ATHENS Melanoma Study Group; 23andMe; SDH Study Group; IBD Investigators; Essen-Heidelberg Investigators; AMFS Investigators; MelaNostrum Consortium, Peris K, Chanock SJ, Demenais F, Brown KM, Puig S, Nagore E, Shi J, Iles MM, Law MH. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. **Nat Genet.** 2020 Apr 27. doi: 10.1038/s41588-020-0611-8.
9. Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, **Mandala M**, Wilmott JS, Menzies AM, Leduc C, Stagg J, Routy B, Long GV, Scolyer RA, Bald T, Waddell N, Dougall WC, Teng MWL, Smyth MJ. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. **Clin Cancer Res.** 2020 Apr 28 doi: 10.1158/1078-0432.
10. Pastorino L, Andreotti V, Dalmasso B, Vanni I, Ciccarese G, **Mandalà M**, Spadola G, Pizzichetta MA, Ponti G, Tibiletti MG, Sala E, Genuardi M, Chiurazzi P, Maccanti G, Manoukian S, Sestini S, Danesi R, Zampiga V, Starza R, Stanganelli I, Ballestrero A, Mastracci L, Grillo F, Sciallero S, Cecchi F, Tanda ET, Spagnolo F, Queirolo P, Imi IMI, Goldstein AM, Bruno W, Ghiorzo P. Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in *ACD*, *ATM*, *BAP1*, and *POT1*. **Cancers (Basel).** 2020 Apr doi: 10.3390/cancers12041007.
11. Portelli F, Galli F, Cattaneo L, Cossa M, De Giorgi V, Forte G, Fraternali Orcioni G, Gianatti A, Indini A, Labianca A, Maurichi A, Merelli B, Montesco MC, Occelli M, Patuzzo R, Piazzalunga D, Pigozzo J, Quaglino P, Ribero S, Salvatori R, Saraggi D, Sena P, Senetta R, Valeri B, Tanaka M, Fukayama M, Palmieri G, **Mandalà M**, Massi D; Italian Melanoma Intergroup (IMI). The prognostic impact of the extent of ulceration in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI). **Br J Dermatol.** 2020 Apr 13. doi: 10.1111/bjd.19120.

12. Indini A, Sessa M, Merelli B, Foresti C, **Mandalà M**. A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy. **Eur J Cancer**. 2020 Apr;129:1-3. doi: 10.1016/j.ejca.2020.01.009.
13. Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF_{V600}-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. **Lancet Oncol**. 2020 Mar;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0.
14. Palmieri M, Baldassarri M, Fava F, Fabbiani A, Gelli E, Tita R, Torre P, Petrioli R, Hadijstilianou T, Galimberti D, Cinotti E, Bengala C, **Mandalà M**, Piu P, Miano ST, Martellucci I, Vannini A, Pinto AM, Mencarelli MA, Marsili S, Renieri A, Frullanti E. Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients. **Cancer Med**. 2020 Mar;9(6):2052-2061. doi: 10.1002/cam4.2782.
15. Ascierto PA, Lewis KD, Di Giacomo AM, Demidov L, **Mandalà M**, Bondarenko I, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Simmons B, Ye C, Hooper G, Wongchenko MJ, Goodman GR, Yan Y, Schadendorf D. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF_{V600}-mutation-positive melanoma receiving adjuvant vemurafenib. **Ann Oncol**. 2020 Jan;31(1):153-159. doi: 10.1016/j.annonc.2019.10.002.
16. Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, **Mandala M**, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, de Groot JWB, Loquai C, Gollerkeri A, Pickard MD, Robert C. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. **Eur J Cancer**. 2020 Feb;126:33-44. doi: 10.1016/j.ejca.2019.11.016.
17. Eggermont AMM, Kicinski M, Blank CU, **Mandala M**, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suci S. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. **JAMA Oncol**. 2020 Jan 2. doi: 10.1001/jamaoncol.2019.5570.
18. Massi D, Rulli E, Cossa M, Valeri B, Rodolfo M, Merelli B, De Logu F, Nassini R, Del Vecchio M, Di Guardo L, De Penni R, Guida M, Sileni VC, Di Giacomo AM, Tucci M, Occhelli M, Portelli F, Vallacchi V, Consoli F, Quagliano P, Queirolo P, Baroni G, Carnevale-Schianca F, Cattaneo L, Minisini A, Palmieri G, Rivoltini L, **Mandalà M**; Italian Melanoma Intergroup. The density and spatial tissue distribution of CD8₊ and CD163₊ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. **J Immunother Cancer**. 2019 Nov 15;7(1):308. doi: 10.1186/s40425-019-0797-4.
19. Schadendorf D, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, **Mandala M**, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young

- TC, Nathan P. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). **Eur J Cancer**. 2019 Nov;121:144-153. doi: 10.1016/j.ejca.2019.08.014.
20. Scatena C, Franceschi S, Franzini M, Sanguinetti C, Romiti N, Caponi L, Mandalà M, Mazzanti CM, Naccarato AG. Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAF(v600e) mutated melanoma cells in vitro. **Cancer Cell Int**. 2019 Aug 28;19:223. doi: 10.1186/s12935-019-0938-3.
 21. Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Schadendorf D. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). **Eur J Cancer**. 2019 Aug 21;119:168-178. doi: 10.1016/j.ejca.2019.07.010.
 22. Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liskay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. **Eur J Cancer**. 2019 Aug 19;119:97-106. doi: 10.1016/j.ejca.2019.07.016.
 23. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. **Ann Oncol**. 2019 Aug 13. pii: mdz221. doi: 10.1093/annonc/mdz221.
 24. Casula M, Paliogiannis P, Ayala F, De Giorgi V, Stanganelli I, Mandalà M, Colombino M, Manca A, Sini MC, Caracò C, Ascierto PA, Satta RR; Melanoma Unit of Sassari (MUS), Lissia A, Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI). Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. **BMC Cancer**. 2019 Aug 5;19(1):772. doi: 10.1186/s12885-019-5984-7.
 25. Rulli E, Legramandi L, Salvati L and **Mandala M**. The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis. **Cancer**. 2019 Jul 9. doi: 10.1002/cncr.32375.
 26. Eggermont AMM, Blank CU, **Mandala M**, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suci S, Robert C. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. **Eur J Cancer**. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020.

27. Testori AAE, Ribero S, Indini A, Mandalà M. Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. **Am J Clin Dermatol**. 2019 Jun 8. doi: 10.1007/s40257-019-00456-4.
28. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, **Mandalà M**, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. **N Engl J Med**. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059.
29. Ombra MN, Paliogiannis P, Stucci LS, Colombino M, Casula M, Sini MC, Manca A, Palomba G, Stanganelli I, Mandalà M, Gandini S, Lissia A, Doneddu V, Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI). Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective. **Nutr Metab (Lond)**. 2019 May 21;16:33. doi: 10.1186/s12986-019-0365-4.
30. Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A. Reply to E. Hindié and K.R. Hess. **J Clin Oncol**. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004.
31. Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. **Lancet Oncol**. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9.
32. Indini A, Tondini CA, Mandalà M. Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival. **Future Oncol**. 2019 Mar;15(9):967-977. doi: 10.2217/fon-2018-0659.
33. Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C. An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. **Eur J Cancer**. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018.
34. Mandalà M, Rutkowski P. Rational combination of cancer immunotherapy in melanoma. **Virchows Arch**. 2019 Apr;474(4):433-447. doi: 10.1007/s00428-018-2506-y.
35. Ribero S, Galli F, Osella-Abate S, Bertero L, Cattaneo L, Merelli B, Tondini C, Ghilardi L, De Giorgi V, Occelli M, Quaglino P, Cassoni P, Palmieri G, Massi D, Mandala M; Italian Melanoma Intergroup. Prognostic impact of regression in patients with primary cutaneous

- melanoma >1 mm in thickness. **J Am Acad Dermatol**. 2019 Jan;80(1):99-105.e5. doi: 10.1016/j.jaad.2018.06.054.
36. Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. **J Clin Oncol**. 2018 Oct 22;JCO1801219. doi: 10.1200/JCO.18.01219.
 37. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liskay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. **Lancet Oncol**. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2.
 38. Palmieri G, Colombino M, Casula M, Manca A, Mandalà M, Cossu A; Italian Melanoma Intergroup (IMI). Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches. **Curr Oncol Rep**. 2018 Sep 14;20(11):86. doi: 10.1007/s11912-018-0733-7.
 39. Stratigos AJ, Fargnoli MC, De Nicolo A, Peris K, Puig S, Soura E, Menin C, Calista D, Ghiorzo P, Mandala M, Massi D, Rodolfo M, Del Regno L, Stefanaki I, Gogas H, Bataille V, Tucker MA, Whiteman D, Nagore E, Landi MT. MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium. **J Eur Acad Dermatol Venereol**. 2018 Dec;32(12):2134-2141. doi: 10.1111/jdv.15208.
 40. Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. **Lancet**. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1.
 41. Audrito V, Managò A, Zamporlini F, Rulli E, Gaudino F, Madonna G, D'Atri S, Antonini Cappellini GC, Ascierto PA, Massi D, Raffaelli N, Mandalà M, Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma. **Oncotarget**. 2018 Apr 10;9(27):18997-19005. doi: 10.18632/oncotarget.24871.
 42. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciú S,

- Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. **N Engl J Med**. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357.
43. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liskay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. **Lancet Oncol**. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6.
 44. Mandalà M, Merelli B, Indriolo A, Tondini C. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient. **Eur J Cancer**. 2018 May;95:130-132. doi: 10.1016/j.ejca.2018.02.019.
 45. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. **JAMA Oncol**. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
 46. Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP. Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. **Front Immunol**. 2018 Mar 2;9:403. doi: 10.3389/fimmu.2018.00403.
 47. Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. **Lancet Oncol**. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2.
 48. Pizzichetta MA, Massi D, Mandalà M, Queirolo P, Stanganelli I, De Giorgi V, Ghigliotti G, Cavicchini S, Quaglino P, Corradin MT, Rubegni P, Alaibac M, Astorino S, Ayala F, Magi S, Mazzoni L, Manganoni MA, Talamini R, Serraino D, Palmieri G; Italian Melanoma Intergroup (IMI). Correction to: Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. **J Transl Med**. 2018 Feb 20;16(1):33. doi: 10.1186/s12967-018-1408-8.
 49. Dréno B, Ascierto PA, Atkinson V, Liskay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A. Health-

- related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma. **Br J Cancer**. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488.
50. Audrito V, Managò A, La Vecchia S, Zamporlini F, Vitale N, Baroni G, Cignetto S, Serra S, Bologna C, Stingi A, Arruga F, Vaisitti T, Massi D, Mandalà M, Raffaelli N, Deaglio S. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. **J Natl Cancer Inst**. 2018 Mar 1;110(3). doi: 10.1093/jnci/djx198.
 51. Chiarion Sileni V, Mandalà M, Queirolo P. [Pembrolizumab for the treatment of melanoma: updates and perspectives.]. **Recenti Prog Med**. 2017 Dec;108(12):528-531. doi: 10.1701/2829.28585.
 52. Pizzichetta MA, Massi D, **Mandalà M**, Queirolo P, Stanganelli I, De Giorgi V, Ghigliotti G, Cavicchini S, Quaglino P, Corradin MT, Rubegni P, Alaibac M, Astorino S, Ayala F, Magi S, Mazzoni L, Manganoni MA, Talamini R, Serraino D, Palmieri G; Italian Melanoma Intergroup (IMI). Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. **J Transl Med**. 2017 Nov 7;15(1):227. doi: 10.1186/s12967-017-1332-3.
 53. Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, **Mandalà M**, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A. mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. **Oncotarget**. 2017 May 25;8(41):69204-69218. doi: 10.18632/oncotarget.18213.
 54. Weber J, **Mandala M**, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. **N Engl J Med**. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030.
 55. Long GV, Hauschild A, Santinami M, Atkinson V, **Mandalà M**, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. **N Engl J Med**. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539.
 56. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, **Mandalà M**, Haanen J, BLAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib

- combination therapy phase 3 randomised trials. **Eur J Cancer**. 2017 Sep;82:45-55. doi: 10.1016/j.ejca.2017.05.033.
57. Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, **Mandalà M**, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. **Eur J Cancer**. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007.
58. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, **Mandalà M**, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. **Ann Oncol**. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.
59. O'Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. **Semin Cancer Biol**. 2018 Feb; 48: 91-103. doi: 10.1016/j.semcancer.2017.04.015.
60. **Mandalà M**, Tondini C, Merelli B, Massi D. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. **Am J Clin Dermatol**. 2017 Oct;18(5):597-611. doi: 10.1007/s40257-017-0282-0.
61. Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, Bieche I, Baroni G, Cattaneo L, Xue G, **Mandalà M**. Baseline β -catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. **Eur J Cancer**. 2017 Jun;78:70-81. doi: 10.1016/j.ejca.2017.03.012.
62. Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, **Mandalà M**, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. **Ann Oncol**. 2018 Feb 1;29(2):524. doi: 10.1093/annonc/mdx059.
63. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, **Mandalà M**, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. **Lancet Oncol**. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8.

64. Perico L, **Mandalà M**, Schieppati A, Carrara C, Rizzo P, Conti S, Longaretti L, Benigni A, Remuzzi G. BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. **Am J Kidney Dis**. 2017 Jul;70(1):145-150. doi: 10.1053/j.ajkd.2016.12.013.
65. Mandalà M, Massi D. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma. **Handb Exp Pharmacol**. 2018;249:129-143. doi: 10.1007/164_2017_5.
66. Audrito V, Serra S, Stingi A, Orso F, Gaudino F, Bologna C, Neri F, Garaffo G, Nassini R, Baroni G, Rulli E, Massi D, Oliviero S, Piva R, Taverna D, **Mandalà M**, Deaglio S. PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. **Oncotarget**. 2017 Feb 28;8(9):15894-15911. doi: 10.18632/oncotarget.15213.
67. **Mandalà M**, De Logu F, Merelli B, Nassini R, Massi D. Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. **Lab Invest**. 2017 Feb;97(2):166-175. doi: 10.1038/labinvest.2016.132.
68. Mandalà M, Galli F, Cattaneo L, Merelli B, Rulli E, Ribero S, Quaglino P, De Giorgi V, Pigozzo J, Sileni VC, Chirco A, Ferrucci PF, Occelli M, Imberti G, Piazzalunga D, Massi D, Tondini C, Queirolo P; Italian Melanoma Intergroup. Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. **J Am Acad Dermatol**. 2017 Feb;76(2):264-273.e2. doi: 10.1016/j.jaad.2016.08.066.
69. Tang H, Massi D, Hemmings BA, **Mandalà M**, Hu Z, Wicki A, Xue G. AKT-ions with a TWIST between EMT and MET. **Oncotarget**. 2016 Sep 20;7(38):62767-62777. doi: 10.18632/oncotarget.11232.
70. **Mandalà M**, Merelli B, Massi D. PD-L1 in melanoma: facts and myths. **Melanoma Manag**. 2016 Sep;3(3):187-194. doi: 10.2217/mmt-2016-0013.
71. Amaro A, Parodi F, Diedrich K, Angelini G, Götz C, Viaggi S, Maric I, Coviello D, Pistillo MP, Morabito A, Mandalà M, Ghiorzo P, Visconti P, Gualco M, Anselmi L, Puzone R, Lanza F, Mosci C, Raggi F, Bosco MC, Varesio L, Zeschnigk M, Spano L, Queirolo P, Pfeffer U. Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma. **JAMA Ophthalmol**. 2016 Oct 1;134(10):1125-1133. doi: 10.1001/jamaophthalmol.2016.2691.
72. Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liskay G, Di Giacomo AM, **Mandalà M**, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. **Lancet Oncol**. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X.
73. Xue G, Romano E, Massi D, Mandalà M. Wnt/ β -catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. **Cancer Treat Rev**. 2016 Sep;49:1-12. doi: 10.1016/j.ctrv.2016.06.009.
74. Falanga A, Marchetti M, Massi D, Merelli B, Verzeroli C, Russo L, Rulli E, Tondini C, Legramandi L, Nassini R, Scatena C, De Logu F, Cattaneo L, **Mandalà M**. Thrombophilic

- status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. *J Am Acad Dermatol*. 2016 Jun;74(6):1254-1256.e4. doi: 10.1016/j.jaad.2015.11.006.
75. Wicki A, **Mandalà M**, Massi D, Taverna D, Tang H, Hemmings BA, Xue G. Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. *Physiol Rev*. 2016 Jul;96(3):805-29. doi: 10.1152/physrev.00024.2015.
 76. Falanga A, Santoro A, Labianca R, De Braud F, Gasparini G, D'Alessio A, Barni S, Iacoviello L; HYPERCAN Study Group. Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. *Thromb Res*. 2016 Apr;140 Suppl 1:S55-9. doi: 10.1016/S0049-3848(16)30099-8.
 77. Massi D, De Giorgi V, Mandalà M. The complex management of atypical Spitz tumours. *Pathology*. 2016 Feb;48(2):132-41. doi: 10.1016/j.pathol.2015.12.003.
 78. Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2016 Apr;100:88-98. doi: 10.1016/j.critrevonc.2016.02.001.
 79. Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. *Ann Oncol*. 2016 Apr;27(4):732-8. doi: 10.1093/annonc/mdw016.
 80. Bruno W, Pastorino L, Ghiorzo P, Andreotti V, Martinuzzi C, Menin C, Elefanti L, Stagni C, Vecchiato A, Rodolfo M, Maurichi A, Manoukian S, De Giorgi V, Savarese I, Gensini F, Borgognoni L, Testori A, Spadola G, Mandalà M, Imberti G, Savoia P, Astrua C, Ronco AM, Farnetti A, Tibiletti MG, Lombardo M, Palmieri G, Ayala F, Ascierto P, Ghigliotti G, Muggianu M, Spagnolo F, Picasso V, Tanda ET, Queirolo P, Bianchi-Scarrà G. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. *J Am Acad Dermatol*. 2016 Feb;74(2):325-32. doi: 10.1016/j.jaad.2015.09.053.
 81. Xue G, Zippelius A, Wicki A, Mandalà M, Tang F, Massi D, Hemmings BA. Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy. *J Natl Cancer Inst*. 2015 Jun 11;107(7). pii: djv171. doi: 10.1093/jnci/djv171.
 82. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet*. 2015 Aug 1;386(9992):444-51. doi: 10.1016/S0140-6736(15)60898-4.

83. Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. **Ann Oncol**. 2015 Sep;26(9):1980-7. doi: 10.1093/annonc/mdv255.
84. Del Vecchio M, Ascierto PA, Mandalà M, Sileni VC, Maio M, Di Guardo L, Simeone E, Queirolo P. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. **Future Oncol**. 2015;11(9):1355-62. doi: 10.2217/fon.15.55.
85. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. **Eur J Cancer**. 2015 May;51(7):833-40. doi: 10.1016/j.ejca.2015.03.004.
86. Massi D, Mandalà M. Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy? **Melanoma Manag**. 2015 Feb;2(1):5-8. doi: 10.2217/mmt.14.27.
87. Massi D, Simi L, Sensi E, Baroni G, Xue G, Scatena C, Caldarella A, Pinzani P, Fontanini G, Carobbio A, Urso C, Mandalà M. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. **Mod Pathol**. 2015 Apr;28(4):487-97. doi: 10.1038/modpathol.2014.137.
88. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liskay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. **N Engl J Med**. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868.
89. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probst V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. **N Engl J Med**. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.
90. Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S, Mandalà M. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. **Ann Oncol**. 2014 Dec;25(12):2433-42. doi: 10.1093/annonc/mdu452.

91. Mandalà M, Merelli B, Massi D. Nras in melanoma: targeting the undruggable target. **Crit Rev Oncol Hematol**. 2014 Nov;92(2):107-22. doi: 10.1016/j.critrevonc.2014.05.005.
92. Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. **J Transl Med**. 2014 May 7;12:116. doi: 10.1186/1479-5876-12-116.
93. Ascierto PA, Chiarion-Sileni V, Muggiano A, Mandalà M, Pimpinelli N, Del Vecchio M, Rinaldi G, Simeone E, Queirolo P. Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. **J Chemother**. 2014 Aug; 26(4): 193-201. doi: 10.1179/1973947813Y.0000000154.
94. Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, Marchetti P, De Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quaglino P, Carnevale Schianca F, Mandalà M, Di Guardo L, Del Vecchio M. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. **Br J Cancer**. 2014 Apr 2;110(7):1721-6. doi: 10.1038/bjc.2014.126.
95. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hossers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. **Lancet Oncol**. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8.
96. Mandalà M, Massi D. Tissue prognostic biomarkers in primary cutaneous melanoma. **Virchows Arch**. 2014 Mar; 464(3): 265-81. doi: 10.1007/s00428-013-1526-x.
97. Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. **Cancer Invest**. 2014; 32: 144-9. doi: 10.3109/07357907.2014.885984.
98. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D; ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **Ann Oncol**. 2013 Oct;24 Suppl 6:vi64-72. doi: 10.1093/annonc/mdt354.
99. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. **Ann Oncol**. 2013 Nov;24(11):2911-5. doi: 10.1093/annonc/mdt376.

100. Merelli B, Massi D, Cattaneo L, Mandalà M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. **Crit Rev Oncol Hematol**. 2014 Jan;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002.
101. Agnelli G, Verso M, Mandalà M, Gallus S, Cimminiello C, Apolone G, Di Minno G, Maiello E, Prandoni P, Santoro A, Crinò L, Labianca R. A prospective study on survival in cancer patients with and without venous thromboembolism. **Intern Emerg Med**. 2014 Aug;9(5):559-67. doi: 10.1007/s11739-013-0985-z.
102. Mandalà M, Massi D, De Giorgi V. Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action. **Crit Rev Oncol Hematol**. 2013;88:318-37doi: 10.1016/j.critrevonc.2013.06.002.
103. Mandalà M, Gianatti A, Massi D. Squamoproliferative skin lesion during braf inhibitors:one size does not fit all. **J Eur Acad Dermatol Venereol**. 2014 Mar;28(3):389-91. doi: 10.1111/jdv.12196.
104. Chiarion-Sileni V, Guida M, Romanini A, Bernengo MG, Ascierto P, Queirolo P, Mandalà M, Maio M, Ferraresi V, Stanganelli I, Testori A, Ridolfi R. Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma. **Dermatology**. 2013;226 Suppl 1:22-7. doi: 10.1159/000348870.
105. Mandalà M, Voit C. Targeting BRAF in melanoma: biological and clinical challenges. **Crit Rev Oncol Hematol**. 2013 Sep;87(3):239-55. doi: 10.1016/j.critrevonc.2013.01.003.
106. Grosso F, Mandalà M, Maglione V, Berretta L, Mariani N, Rossi M, Piovano PL, Drago D, Summa M, Franzone P, Musante F, Spinoglio G. Neoadjuvant therapy and mini-invasive total mesorectal excision for rectal cancer: feasibility and outcome analysis from a single institution prospectively collected data base. **Tumori**. 2012 Nov; 98(6): 689-95. doi: 10.1700/1217.13490.
107. Mandalà M, Faggioli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R, Roila F. Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. **Crit Rev Oncol Hematol**. 2013 Jul;87(1):12-27. doi: 10.1016/j.critrevonc.2012.12.004.
108. Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brillhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Büller HR, Bounameaux H. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. **J Thromb Haemost**. 2013 Jan;11(1):71-80. doi: 10.1111/jth.12071.
109. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brillhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. **J Thromb Haemost**. 2013 Jan;11(1):56-70. doi: 10.1111/jth.12070.

- 110.Mandalà M, Tondini C. Adjuvant therapy in breast cancer and venous thromboembolism. *Thromb Res.* 2012 Oct;130 Suppl 1:S66-70. doi: 10.1016/j.thromres.2012.08.280.
- 111.Mandalà M, Grosso F, Vitalini C, Corradino I, Sanfilippo R, Colombini S, Clerici M, Labianca R, De Pascale A, Marsoni S. Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies. *Br J Cancer.* 2012 Aug 7;107(4):612-6. doi: 10.1038/bjc.2012.325.
- 112.Mandalà M, Grosso F. Is the pooled analysis of the north central cancer treatment group phase III trials N9741 and N9841 biased? *J Clin Oncol.* 2012 May 20;30(15):1894-5; author reply 1895. doi: 10.1200/JCO.2012.41.9374.
- 113.Mandala M, Clerici M, Corradino I, Vitalini C, Colombini S, Torri V, De Pascale A, Marsoni S. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. *Ann Oncol.* 2012 Jun;23(6):1416-21. doi: 10.1093/annonc/mdr524.
- 114.Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M, Brighenti M, Petrelli F, Bianchini C, Perrone T, Gasparini G. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. *J Transl Med.* 2011 Oct 20;9:179. doi: 10.1186/1479-5876-9-179.
- 115.Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2011 Sep;22 Suppl 6:vi85-92. doi: 10.1093/annonc/mdr392.
- 116.Mandalà M, Tondini C. The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer. *Expert Rev Anticancer Ther.* 2011 Apr;11(4):579-88. doi: 10.1586/era.10.184.
- 117.Mandalà M, Imberti GL, Piazzalunga D, Belfiglio M, Lucisano G, Labianca R, Marchesi L, Merelli B, Robone S, Poletti P, Milesi L, Tondini C. Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma. *Mayo Clin Proc.* 2011 Feb;86(2):113-9. doi: 10.4065/mcp.2010.0671
- 118.Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicoletta D, Aglietta M, Lonardi S, Corsi D, Turci D, Beretta GD, Fornarini G, Dapretto E, Floriani I, Zaniboni A; Italian Group for the Study of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. *Ann Oncol.* 2011 May;22(5):1236-42. doi: 10.1093/annonc/mdq580.
- 119.Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. *Ann Oncol.* 2010 May;21 Suppl 5:v274-6. doi: 10.1093/annonc/mdq199.
- 120.Mandalà M, Labianca R; European Society for Medical Oncology. Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management. *Thromb Res.* 2010 Apr;125 Suppl 2:S117-9. doi: 10.1016/S0049-3848(10)70028-1.

121. Gaspari F, Cravedi P, Mandalà M, Perico N, de Leon FR, Stucchi N, Ferrari S, Labianca R, Remuzzi G, Ruggenti P. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. *Nephron Clin Pract.* 2010;115(2):c154-60. doi: 10.1159/000312879.
122. Mandala M, Falanga A, Labianca R. Video meliora proboque sed deteriora sequor: the case of thromboprophylaxis in hospitalized cancer patients. *Ann Oncol.* 2010 May;21(5):911-3. doi: 10.1093/annonc/mdp500.
123. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. *Lancet Oncol.* 2009 Oct;10(10):943-9. doi: 10.1016/S1470-2045(09)70232-3.
124. Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. *J Clin Oncol.* 2009 Oct 10;27(29):4919-26. doi: 10.1200/JCO.2009.22.3214.
125. Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. *Ann Oncol.* 2010 Apr;21(4):871-6. doi: 10.1093/annonc/mdp354.
126. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. *Ann Oncol.* 2009 May;20 Suppl 4:182-4. doi: 10.1093/annonc/mdp167. Review. PubMed PMID: 19454449.
127. Mandalà M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, Marchesi L, Poletti P, Bonomi L, Novellino L, Di Biagio K, Milesi A, Guerra U, Tondini C. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. *Eur J Cancer.* 2009 Sep;45(14):2537-45. doi: 10.1016/j.ejca.2009.05.034.
128. Mandalà M, Barni S, Floriani I, Isa L, Fornarini G, Marangolo M, Mosconi S, Corsi D, Rulli E, Frontini L, Cortesi E, Zaniboni A, Aglietta M, Labianca R. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. *Eur J Cancer.* 2009 Jan;45(1):65-73. doi: 10.1016/j.ejca.2008.09.005.
129. Curigliano G, Mandalà M, Sbanotto A, Colleoni M, Ferretti G, Bucciarelli P, Peruzzotti G, de Braud F, De Pas T, Spitaleri G, Pietri E, Orsi F, Banfi MG, Goldhirsch A. Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. *Support Cancer Ther.* 2006 Jan 1;3(2):98-102. doi: 10.3816/SCT.2006.n.005.
130. Labianca R, Mandalà M, Clerici M. [Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy]. *Tumori.* 2008 Mar-Apr;94(2):suppl 23-5.

131. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. *Ann Oncol*. 2008 May;19 Suppl 2:ii126-7. doi: 10.1093/annonc/mdn110.
132. Mandalà M, Moro C, Labianca R, Cremonesi M, Barni S. Optimizing use of opiates in the management of cancer pain. *Ther Clin Risk Manag*. 2006 Dec;2(4):447-53.
133. Mandalà M, Moro C, Labianca R. Venous thromboembolism and pancreatic cancer: incidence, pathogenesis and clinical implications. *Onkologie*. 2008 Mar;31(3):129-35. doi: 10.1159/000113533.
134. Ferretti G, Felici A, Cognetti F, Mandala M. Transforming growth factor-beta signaling and regulatory T cells. *J Clin Oncol*. 2007 Oct 10;25(29):4695-6.
135. Mandalà M, Moro C, Labianca R, Ferretti G. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial? *J Clin Oncol*. 2007 Sep 20;25(27):4320-1.
136. Mandalà M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S, Berardi R, Mosconi S, Torri V, Labianca R. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. *Ann Oncol*. 2007 Oct;18(10):1660-5.
137. Mandalà M, Pezzica E, Tamborini E, Guerra U, Lagonigro SM, Forloni B, Barni S. Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome. *Eur J Gastroenterol Hepatol*. 2007 Aug;19(8):711-3.
138. Mandalà M, Mosconi S, Quadri A, Milesi L, Labianca R. Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer. *Expert Rev Anticancer Ther*. 2007 Jun;7(6):887-97.
139. Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalà M, Papaldo P, Fabi A, Ciccarese M, Cuppone F, Cecere FL, Nuzzo C, Terzoli E, Cognetti F. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? *Chest*. 2006 Dec;130(6):1808-16.
140. Mandalà M, Moro C, Michetti G, Ferretti G, Labianca R. What is the real benefit of adjuvant chemotherapy in the Adjuvant Navelbine International Trialist Association trial? *Ann Oncol*. 2007 Feb;18(2):404.
141. Ferretti G, Giannarelli D, Carlini P, Felici A, Ciccarese M, Mandalà M, Cognetti F. Self-monitoring versus standard monitoring of oral anticoagulation. *Thromb Res*. 2007;119(3):389-90.
142. Mandalà M, Falanga A, Piccioli A, Prandoni P, Pogliani EM, Labianca R, Barni S; working group AIOM. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). *Crit Rev Oncol Hematol*. 2006 Sep;59(3):194-204.
143. Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalà M, Ciccarese M, Papaldo P, Fabi A, Cognetti F. Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. *Thromb Res*. 2007;119(4):525-9.

144. Ferretti G, Felici A, Cognetti F, Mandalà M. Is there a right-sided shift for colorectal cancer in women compared with men? *Cancer Epidemiol Biomarkers Prev.* 2006 May;15(5):1054.
145. Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalà M, Papaldo P, Fabi A, Ciccicarese M, Cognetti F. Does low-molecular-weight heparin influence cancer-related mortality? *Ann Oncol.* 2006 Oct;17(10):1604-6.
146. Moro C, Taino R, Mandalà M, Labianca R. Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy. *Ann Oncol.* 2006 Sep;17(9):1466-7. Epub 2006 Apr 26.
147. Barni S, Mandalà M, Cazzaniga M, Cabiddu M, Cremonesi M. Bisphosphonates and metastatic bone disease. *Ann Oncol.* 2006 Mar;17 Suppl 2:ii91-95.
148. Mandalà M, Falanga A, Cremonesi M, Zaccanelli M, Floriani I, Viganò MG, Rosti A, Cazzaniga ME, Ferretti G, Cabiddu M, Barni S. The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma. *Thromb Haemost.* 2006 Apr;95(4):752-4. PubMed PMID: 16601855.
149. Barni S, Mandalà M. Locally advanced breast cancer. *Curr Opin Obstet Gynecol.* 2006 Feb;18(1):47-52.
150. Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalà M, Papaldo P, Nistico C, Fabi A, Cuppone F, Gelibter A, Terzoli E, Cognetti F. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality? *J Clin Oncol.* 2005 Oct 1;23(28):7248-50.
151. Curigliano G, Colleoni M, Mandalà M, De Pas T, Spitaleri G, de Braud F, Goldhirsch A. Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. *J Clin Oncol.* 2005 Oct 1;23(28):7243-4.
152. Barni S, Mandalà M. Chemotherapy for metastatic breast cancer. *Ann Oncol.* 2005 May;16 Suppl 4:iv23-27.
153. Ferretti G, Mandalà M, Bria E, Papaldo P, Carlini P, Fabi A, Milella M, Ruggeri EM, Nisticò C, Cognetti F. Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury? *Ann Oncol.* 2005 Aug;16(8):1403-4.
154. Ferretti G, Mandalà M, Bria E, Carlini P, Papaldo P, Fabi A, Felici A, Cognetti F. Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer. *Breast Cancer Res Treat.* 2005 Apr;90(3):319.
155. Ferretti G, Bria E, Mandalà M. Chemoradiotherapy for rectal cancer. *N Engl J Med.* 2005 Feb 3;352(5):509-11.
156. Mandalà M, Cremonesi M, Rocca A, Cazzaniga M, Ferretti G, Di Cosimo S, Ghilardi M, Cabiddu M, Barni S. Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. *Support Care Cancer.* 2005 Jun;13(6):375-80.
157. Mandalà M, Ferretti G, Barni S. Oxaliplatin in colon cancer. *N Engl J Med.* 2004 Oct 14;351(16):1691-2.

158. Barni S, Piazza E, Frontini L, Visini M, Ardizzioia A, Grassi MM, Nosenzo MA, Mandalà M, Biasioli R, Freddi E, Lucani L, Recalcati A, Pravettoni A, Sala R, Rezzani C, Villa S, Trabucchi E; Neo-Adjuvant Breast Italian Group. Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up. *Oncology*. 2004;67(1):40-7.
159. Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandalà M, Milella M, Ruggeri EM, Cognetti F. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. *Ann Oncol*. 2004 Jul;15(7):1065-71.
160. Mandalà M, Ciano C, Ghilardi M, Cremonesi M, Cazzaniga M, Barni S. Acute dyspnea due to right phrenic palsy during infusional chemotherapy. *Ann Oncol*. 2004 Apr;15(4):691-2.
161. Mandalà M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci PG, Biffi R, Orsi F, Cinieri S, Goldhirsch A. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. *Ann Oncol*. 2004 Apr;15(4):590-3.
162. Mandalà M, Cremonesi M, Cazzaniga M, Rezzani C, Ghilardi M, Mary C, Ferretti G, Barni S. Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation? *Colorectal Dis*. 2004 Mar;6(2):129-30.
163. Ferretti G, Di Cosimo S, Giannarelli D, Carlini P, Papaldo P, Alimonti A, Fabi A, Mandalà M, Milella M, Ruggeri EM, Cognetti F. HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear? *J Clin Oncol*. 2004 Feb 1;22(3):568-9.
164. Mandalà M, Ferretti G, Cremonesi M, Cazzaniga M, Curigliano G, Barni S. Venous thromboembolism and cancer: new issues for an old topic. *Crit Rev Oncol Hematol*. 2003 Oct;48(1):65-80.
165. Di Cosimo S, Ferretti G, Fazio N, Mandalà M, Curigliano G, Bosari S, Intra M, Latronico A, Goldhirsch A. Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. *Ann Oncol*. 2003 May;14(5):803-4.
166. Di Cosimo S, Pistillucci G, Ferretti G, Cicchetti A, Leggio M, Silvestris N, Moro C, Mandalà M, Curigliano G, Battigaglia B, Di Chio G, Cirignotta S, D'Aprile M. Palliative home care and cost savings: encouraging results from Italy. *N Z Med J*. 2003 Mar 14;116(1170):U370.
167. Ferretti G, Mandalà M, Di Cosimo S, Moro C, Curigliano G, Barni S. Catheter-related bloodstream infections, part II: specific pathogens and prevention. *Cancer Control*. 2003 Jan-Feb;10(1):79-91.
168. Cremonesi M, Mandalà M, Cazzaniga M, Rezzani C, Gambera M, Barni S. Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study. *Oncology*. 2003;64(2):97-101.
169. Ferretti G, Mandalà M, Di Cosimo S, Moro C, Curigliano G, Barni S. Catheter-related bloodstream infections, part I: pathogenesis, diagnosis, and management. *Cancer Control*. 2002 Nov-Dec;9(6):513-23.

170. Mandalà M, Lissoni P, Ferretti G, Rocca A, Torri V, Moro C, Curigliano G, Barni S. Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients. *Oncology*. 2002;63(4):370-7.
171. Mandalà M, Gokina N, Osol G. Contribution of nonendothelial nitric oxide to altered rat uterine resistance artery serotonin reactivity during pregnancy. *Am J Obstet Gynecol*. 2002 Aug;187(2):463-8.
172. Curigliano G, Colleoni M, Renne G, Mazzarol G, Gennari R, Peruzzotti G, de Braud E, Robertson C, Maiorano E, Veronesi P, Nolè F, Mandalà M, Ferretti G, Viale G, Goldhirsch A. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. *Ann Oncol*. 2002 Jun;13(6):895-902.
173. Curigliano G, Mandalà M, Minchella I, Goldhirsch A. Mediastinal lymphadenopathy in a patient with breast cancer. *Lancet Oncol*. 2002 Mar;3(3):174.
174. Curigliano G, Ferretti G, Mandalà M, De Pas T, Calabrò MG, Solli P, Noberasc C, de Braud F. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. *Anticancer Res*. 2001 Sep-Oct;21(5):3461-9.
175. Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, Ferrari-Bravo A, Ferrante R, Vigoré L, Rovelli F, Mandalà M, Viviani S, Fumagalli L, Gardani GS. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. *J Biol Regul Homeost Agents*. 2001 Apr-Jun;15(2):140-4.
176. Lissoni P, Mandalà M, Giani L, Malugani F, Secondino S, Zonato S, Rocco F, Gardani G. Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia. *Neuro Endocrinol Lett*. 2000;21(5):405-408.
177. Lissoni P, Mandalà M, Curigliano G, Ferretti G, Moro C, Ardizzioia A, Malugani F, Tancini G, Tisi E, Arrigoni C, Barni S. Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. *Oncology*. 2001;60(4):308-12.
178. Lissoni P, Mandalà M, Rossini F, Fumagalli L, Barni S. Growth Factors: Thrombopoietic Property of the Pineal Hormone Melatonin. *Hematology*. 1999;4(4):335-343.
179. Barni S, Mandalà M, Gambera M. [Costs, disease management and DRG]. *Tumori*. 2001 Jan-Feb;87(1 Suppl 1):S59. Italian.
180. Mandalà M, Moro C, Ferretti G, Calabro MG, Nolè F, Rocca A, Munzone E, Castro A, Curigliano G. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. *Anticancer Res*. 2001 Jan-Feb;21(1B):585-8.
181. Nolè F, Munzone E, Mandalà M, Catania C, Orlando L, Zampino MG, Minchella I, Colleoni M, Peruzzotti G, Marrocco E, Goldhirsch A. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. *Ann Oncol*. 2001 Jan;12(1):95-100.
182. Mandalà M, Stridsberg M, Helle KB, Serck-Hanssen G. Endothelial handling of chromogranin A. *Adv Exp Med Biol*. 2000;482:167-78.

183. De Pas T, de Braud F, Mandalà M, Curigliano G, Catania C, Ferretti G, Sozzi P, Solli P, Goldhirsch A. Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. *Lung Cancer*. 2001 Feb-Mar;31(2-3):267-70.
184. Colleoni M, Mandalà M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. *Lancet*. 2000 Oct 14;356(9238):1326-7.
185. Lissoni P, Rovelli F, Giani L, Fumagalli L, Mandalà M. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients. *Nat Immun*. 1998;16(5-6):178-84.
186. Ferretti G, Curigliano G, Pastorino U, Cittadini A, Flamini G, Calabrò MG, De Pas T, Orlando L, Mandalà M, Colleoni M, Spaggiari L, Granone PL, Pagliari G, de Braud F, Fazio N, Goldhirsch A. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. *Clin Cancer Res*. 2000 Jun;6(6):2393-400.
187. Lissoni P, Mandalà M, Brivio F. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin. *Eur Urol*. 2000 Jul;38(1):115-8.
188. De Pas TM, Mandalà M, Curigliano G, Peccatori F. Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703. *Obstet Gynecol*. 2000 Jun;95(6 Pt 2):1030.
189. Munzone E, Nolè F, Orlando L, Mandalà M, Biffi R, Ciano C, Villa G, Civelli M, Goldhirsch A. Unexpected right phrenic nerve injury during 5-fluorouracil continuous infusion plus cisplatin and vinorelbine in breast cancer patients. *J Natl Cancer Inst*. 2000 May 3;92(9):755.
190. Bordin V, Giani L, Meregalli S, Bukovec R, Vaghi MM, Mandalà M, Paolorossi F, Ardizzioia A, Tancini G, Barni S, Frigerio F, Fumagalli L, Bordoni A, Valsuani G, Di Felice G, Lissoni P. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. *Urol Int*. 2000; 64(1): 3-8.
191. Mandalà M, Lissoni P, Ardizzioia A, Barni S, Rovelli F, Confalonieri G, Malugani F, Moro C, Fumagalli G, Giani L, Tancini G. Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer. *Tumori*. 1999 Nov-Dec; 85(6): 494-7.
192. Lissoni P, Mandalà M, Rovelli F, Casu M, Rocco F, Tancini G, Scardino E. Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia. *Eur Urol*. 2000 May;37(5):569-72.
193. Lissoni P, Vigore L, Ferranti R, Bukovec R, Meregalli S, Mandalà M, Barni S, Tancini G, Fumagalli L, Giani L. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. *J Biol Regul Homeost Agents*. 1999 Oct-Dec;13(4):216-9.
194. Lissoni P, Barni S, Mandalà M, Ardizzioia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the

- pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. *Eur J Cancer*. 1999 Nov;35(12):1688-92.
195. Lissoni P, Bolis S, Mandalà M, Viviani S, Pogliani E, Barni S. Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2. *Int J Biol Markers*. 1999 Jul-Sep;14(3):167-71.
 196. Barni S, Cascinu S, Foa P, Frontini L, Labianca R, Luporini G, Mandalà M, Martignoni G, Pancera G, Sobrero A, Zaniboni A. [Adjuvant therapy of colon cancer. State of the art and future perspectives]. *Tumori*. 1999 May-Jun;85(3): A1-6.
 197. Lissoni P, Fumagalli L, Paolorossi F, Mandalà M. Changes in lymphocyte number during cancer chemotherapy and their relation to clinical response. *Int J Biol Markers*. 1999 Apr-Jun;14(2):115-7.
 198. Lissoni P, Tancini G, Paolorossi F, Mandalà M, Ardizzoia A, Malugani F, Giani L, Barni S. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. *J Pineal Res*. 1999 Apr;26(3):169-73.
 199. Lissoni P, Rovelli F, Mandalà M, Barni S. Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerations. *Int J Biol Markers*. 1998 Jul-Sep;13(3):169-71.
 200. Lissoni P, Rovelli F, Giani L, Mandala M, Meregalli S, Barni S, Confalonieri G, Bonfanti A. Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease. *Int J Biol Markers*. 1998 Jul-Sep;13(3):154-7.
 201. Corsello SM, Rota CA, Putignano P, Della Casa S, Barnabei A, Migneco MG, Vangeli V, Barini A, Mandalà M, Barone C, Barbarino A. Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer. *Eur J Endocrinol*. 1998 Sep;139 (3): 309-13.
 202. Lissoni P, Mengo S, Mandalà M, Mauri E, Brivio F, Rovelli F, Confalonieri G, Longarini R, Bonfante A, Folli D, Meregalli S, Barni S, Tancini G, Giani L. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy. *J Biol Regul Homeost Agents*. 1998 Jan-Jun;12(1-2): 38-41.
 203. Lissoni P, Rovelli F, Rivolta MR, Frigerio C, Mandalà M, Barni S, Ardizzoia A, Malugani F, Tancini G. Acute endocrine effects of interleukin-12 in cancer patients. *J Biol Regul Homeost Agents*. 1997 Oct Dec; 11 (4): 154-6.

I authorize the use of my personal data in compliance with Legislative Decree 196/2003
I conducted clinical research according to GCP

Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Il dichiarante 

Bergamo, 14.11.2020